Suchergebnisse - "Prostatic Neoplasms"

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.

Autoren: Wang R Xu J Zhu C et al.

Quelle: Cancer research communications [Cancer Res Commun] 2025 Dec 01; Vol. 5 (12), pp. 2092-2101.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

MeSH-Schlagworte: Biomarkers, Tumor*/genetics , Biomarkers, Tumor*/blood , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/blood , Prostatic Neoplasms*/mortality , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/drug therapy , Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics, Humans ; Male ; Aged ; Progression-Free Survival ; Middle Aged ; Mutation ; Prognosis ; PTEN Phosphohydrolase/genetics ; Tumor Suppressor Protein p53/genetics ; Retinoblastoma Binding Proteins/genetics ; Aged, 80 and over ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/blood ; Cyclin-Dependent Kinases ; Ubiquitin-Protein Ligases

Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS).

Autoren: Maughan BL Liu Y Mundle S et al.

Quelle: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2025 Dec; Vol. 28 (4), pp. 865-873. Date of Electronic Publication: 2024 Dec 20.

Publikationsart: Journal Article; Observational Study

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9815755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5608 (Electronic) Linking ISSN: 13657852 NLM ISO Abbreviation: Prostate Cancer Prostatic Dis Subsets: MEDLINE

MeSH-Schlagworte: Thiohydantoins*/therapeutic use , Thiohydantoins*/administration & dosage , Prostatic Neoplasms*/mortality , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/pathology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Retrospective Studies ; Aged ; Middle Aged ; Benzamides/therapeutic use ; Nitriles ; Survival Rate ; Aged, 80 and over ; Follow-Up Studies ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostate-Specific Antigen/blood ; Androgen Antagonists/therapeutic use ; Androgen Receptor Antagonists/therapeutic use ; Treatment Outcome ; Prognosis ; Phenylthiohydantoin

Malonyl-CoA Promotes Prostate Cancer Progression and Castration Resistance by Enhancing Lipogenesis and Ran Activation.

Autoren: Dai Y Liu L Luo Y et al.

Quelle: Cancer research [Cancer Res] 2025 Nov 14; Vol. 85 (22), pp. 4504-4520.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

MeSH-Schlagworte: Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Lipogenesis* , Malonyl Coenzyme A*/metabolism, Male ; Humans ; Animals ; Disease Progression ; Mice ; Receptors, Androgen/metabolism ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Gene Expression Regulation, Neoplastic ; Mitochondria/metabolism ; Mice, Nude ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/metabolism

Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression.

Autoren: Venkadakrishnan VB Presser A Voss NCE et al.

Quelle: Cancer research [Cancer Res] 2025 Oct 15; Vol. 85 (20), pp. 3842-3854.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

MeSH-Schlagworte: Tumor Suppressor Proteins*/genetics , Tumor Suppressor Proteins*/metabolism , Homeodomain Proteins*/genetics , Homeodomain Proteins*/metabolism , Epigenesis, Genetic* , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/metabolism , Gene Expression Regulation, Neoplastic* , Carcinoma, Neuroendocrine*/genetics , Carcinoma, Neuroendocrine*/pathology , Neuroendocrine Tumors*/genetics , Neuroendocrine Tumors*/pathology, Male ; Humans ; Prospero-Related Homeobox 1 Protein ; Animals ; Mice ; Disease Progression ; Cell Line, Tumor ; Phosphorylation ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology

PPP1R14B promotes the progression of prostate cancer by regulating the JAK2/STAT3/AR pathway and alters the sensitivity and resistance to enzalutamide.

Autoren: Cheng L You C Ma L et al.

Quelle: Cellular signalling [Cell Signal] 2025 Dec; Vol. 136, pp. 112163. Date of Electronic Publication: 2025 Oct 09.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8904683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3913 (Electronic) Linking ISSN: 08986568 NLM ISO Abbreviation: Cell Signal Subsets: MEDLINE

MeSH-Schlagworte: Phenylthiohydantoin*/pharmacology , Phenylthiohydantoin*/analogs & derivatives , Phenylthiohydantoin*/therapeutic use , STAT3 Transcription Factor*/metabolism , Janus Kinase 2*/metabolism , Benzamides*/pharmacology , Drug Resistance, Neoplasm*/drug effects , Receptors, Androgen*/metabolism , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/metabolism , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/genetics , Protein Phosphatase 1*/metabolism , Protein Phosphatase 1*/genetics, Male ; Humans ; Nitriles/pharmacology ; Cell Line, Tumor ; Disease Progression ; Signal Transduction/drug effects ; Cell Proliferation/drug effects ; Animals ; Mice ; Mice, Nude ; Cell Movement/drug effects ; Gene Expression Regulation, Neoplastic/drug effects ; Prostatic Neoplasms, Castration-Resistant

WTAP-mediated m ⁶ A modification promotes drug sensitivity by regulating NR3C1 in prostate cancer.

Autoren: Wang H Zhang D Ouyang Y et al.

Quelle: Science China. Life sciences [Sci China Life Sci] 2025 Nov; Vol. 68 (11), pp. 3151-3166. Date of Electronic Publication: 2025 Jul 08.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Science China Press, co-published with Springer Country of Publication: China NLM ID: 101529880 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1869-1889 (Electronic) Linking ISSN: 16747305 NLM ISO Abbreviation: Sci China Life Sci Subsets: MEDLINE

MeSH-Schlagworte: Adenosine*/analogs & derivatives , Adenosine*/metabolism , Prostatic Neoplasms, Castration-Resistant*/metabolism , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology , RNA Splicing Factors*/metabolism , RNA Splicing Factors*/genetics , Receptors, Thyroid Hormone*/metabolism , Receptors, Thyroid Hormone*/genetics, Male ; Humans ; Animals ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Drug Resistance, Neoplasm/genetics ; RNA-Binding Proteins/metabolism ; RNA-Binding Proteins/genetics ; Flutamide/pharmacology ; Mice ; Mice, Nude ; Prostatic Neoplasms/metabolism ; Receptors, Glucocorticoid ; Cell Cycle Proteins

Cellular cartography reveals mouse prostate organization and determinants of castration resistance.

Autoren: Cho H Zhang Y Tien JC et al.

Quelle: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2025 Sep 02; Vol. 122 (35), pp. e2427116122. Date of Electronic Publication: 2025 Aug 25.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE

MeSH-Schlagworte: Prostate*/metabolism , Prostate*/pathology , Prostate*/cytology , Prostatic Neoplasms, Castration-Resistant*/pathology , Prostatic Neoplasms, Castration-Resistant*/genetics , Prostatic Neoplasms, Castration-Resistant*/metabolism, Animals ; Male ; Mice ; Humans ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Transcriptome ; Androgens/metabolism ; Single-Cell Analysis ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/genetics ; Gene Expression Regulation, Neoplastic ; Androgen Antagonists/pharmacology

[Options in nuclear medicine for advanced prostate cancer in practice].

Transliterierter Titel: Nuklearmedizinische Optionen bei fortgeschrittenem Prostatakarzinom in der Praxis.

Autoren: Kunte SC Kazmierczak PM Holzgreve A et al.

Quelle: Urologie (Heidelberg, Germany) [Urologie] 2025 Sep; Vol. 64 (9), pp. 976-985. Date of Electronic Publication: 2025 Aug 18.

Publikationsart: Journal Article; Review; English Abstract

Info zur Zeitschrift: Publisher: Springer Medizin Country of Publication: Germany NLM ID: 9918384886606676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2731-7072 (Electronic) Linking ISSN: 27317064 NLM ISO Abbreviation: Urologie Subsets: MEDLINE

MeSH-Schlagworte: Prostatic Neoplasms*/diagnostic imaging , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/radiotherapy , Positron Emission Tomography Computed Tomography*/methods , Radiopharmaceuticals*/therapeutic use , Nuclear Medicine*/methods , Nuclear Medicine*/trends, Humans ; Male ; Glutamate Carboxypeptidase II ; Prostatic Neoplasms, Castration-Resistant/diagnostic imaging

Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.

Autoren: Fatima Y Jobre KN Gomez-Gomez E et al.

Quelle: International journal of molecular sciences [Int J Mol Sci] 2025 Aug 02; Vol. 26 (15). Date of Electronic Publication: 2025 Aug 02.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH-Schlagworte: Precision Medicine*/methods , Genomics*/methods , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/metabolism, Humans ; Male ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Biomarkers, Tumor/genetics

[Expert consensus on whole-course management of prostate cancer (2025 edition)].

Körperschaften: Genitourinary Oncology Committee of Chinese Anti-Cancer Association

Quelle: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2025 Jul 23; Vol. 47 (7), pp. 617-634.

Publikationsart: English Abstract; Journal Article

Info zur Zeitschrift: Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766 (Print) Linking ISSN: 02533766 NLM ISO Abbreviation: Zhonghua Zhong Liu Za Zhi Subsets: MEDLINE

MeSH-Schlagworte: Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/diagnosis, Humans ; Male ; Consensus ; Prostate-Specific Antigen/blood ; Quality of Life ; Prostatic Neoplasms, Castration-Resistant/therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; China ; Bone Neoplasms/secondary ; Androgen Antagonists/therapeutic use

miRNA-mediated resistance mechanisms in prostate cancer: implications for targeted therapy and metastatic progression.

Autoren: Mostafa MM El-Aziz MKA Ellakwa DE

Quelle: Medical oncology (Northwood, London, England) [Med Oncol] 2025 Aug 29; Vol. 42 (10), pp. 454. Date of Electronic Publication: 2025 Aug 29.

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE

MeSH-Schlagworte: MicroRNAs*/genetics , Drug Resistance, Neoplasm*/genetics , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/therapy , Prostatic Neoplasms*/drug therapy, Humans ; Male ; Disease Progression ; Molecular Targeted Therapy/methods ; Prostatic Neoplasms, Castration-Resistant/genetics ; Neoplasm Metastasis ; Biomarkers, Tumor/genetics

Skin rash induced by apalutamide correlated with age and relative dose intensity adjusted by body surface area in Japanese patients with prostate cancer.

Autoren: Akagi N Obayashi R Yamamoto A et al.

Quelle: Japanese journal of clinical oncology [Jpn J Clin Oncol] 2025 Aug 03; Vol. 55 (8), pp. 963-969.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Oxford University Press Country of Publication: England NLM ID: 0313225 Publication Model: Print Cited Medium: Internet ISSN: 1465-3621 (Electronic) Linking ISSN: 03682811 NLM ISO Abbreviation: Jpn J Clin Oncol Subsets: MEDLINE

MeSH-Schlagworte: Exanthema*/chemically induced , Thiohydantoins*/adverse effects , Thiohydantoins*/administration & dosage , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/pathology , Drug Eruptions*/etiology, Humans ; Male ; Aged ; Retrospective Studies ; Body Surface Area ; Middle Aged ; Aged, 80 and over ; Age Factors ; Japan ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Dose-Response Relationship, Drug ; East Asian People

PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Real-World Analyses?

Autoren: Shimomura T Otsuka N Urabe F et al.

Körperschaften: Shimomura T Otsuka N Urabe F et al.

Quelle: The Prostate [Prostate] 2025 Jun; Vol. 85 (9), pp. 833-840. Date of Electronic Publication: 2025 Apr 06.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8101368 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0045 (Electronic) Linking ISSN: 02704137 NLM ISO Abbreviation: Prostate Subsets: MEDLINE

MeSH-Schlagworte: Prostate-Specific Antigen*/blood , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/mortality , Prostatic Neoplasms*/blood , Prostatic Neoplasms*/pathology , Androgen Receptor Antagonists*/therapeutic use, Humans ; Male ; Aged ; Nitriles/therapeutic use ; Middle Aged ; Benzamides/therapeutic use ; Phenylthiohydantoin/analogs & derivatives ; Phenylthiohydantoin/therapeutic use ; Abiraterone Acetate/therapeutic use ; Retrospective Studies ; Aged, 80 and over ; Treatment Outcome ; Thiohydantoins/therapeutic use ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/mortality ; Prostatic Neoplasms, Castration-Resistant/blood ; Survival Rate ; Neoplasm Metastasis

Characterization of RNA editing gene APOBEC3C as a candidate tumor suppressor in prostate cancer.

Autoren: Wang LY Shi J Wang MF et al.

Quelle: Scientific reports [Sci Rep] 2025 May 22; Vol. 15 (1), pp. 17725. Date of Electronic Publication: 2025 May 22.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

MeSH-Schlagworte: Cytidine Deaminase*/genetics , Cytidine Deaminase*/metabolism , RNA Editing*/genetics , Prostatic Neoplasms*/genetics , Prostatic Neoplasms*/pathology , Genes, Tumor Suppressor*, Humans ; Male ; Gene Expression Regulation, Neoplastic ; Receptors, Androgen/metabolism ; Receptors, Androgen/genetics ; Prostatic Neoplasms, Castration-Resistant/genetics ; Prostatic Neoplasms, Castration-Resistant/pathology ; Drug Resistance, Neoplasm/genetics

The mechanism of histone modifications in regulating enzalutamide sensitivity in advanced prostate cancer.

Autoren: Zhao Z Jing Y Xu Z et al.

Quelle: International journal of biological sciences [Int J Biol Sci] 2025 Apr 13; Vol. 21 (6), pp. 2880-2890. Date of Electronic Publication: 2025 Apr 13 (Print Publication: 2025).

Publikationsart: Journal Article; Review

Info zur Zeitschrift: Publisher: Ivyspring International Country of Publication: Australia NLM ID: 101235568 Publication Model: eCollection Cited Medium: Internet ISSN: 1449-2288 (Electronic) Linking ISSN: 14492288 NLM ISO Abbreviation: Int J Biol Sci Subsets: MEDLINE

MeSH-Schlagworte: Phenylthiohydantoin*/therapeutic use , Phenylthiohydantoin*/analogs & derivatives , Phenylthiohydantoin*/pharmacology , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/metabolism , Histones*/metabolism , Antineoplastic Agents*/therapeutic use, Humans ; Male ; Benzamides ; Nitriles ; Drug Resistance, Neoplasm ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/metabolism

Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial.

Autoren: Burgess EF Grigg CM Boselli D et al.

Quelle: Clinical genitourinary cancer [Clin Genitourin Cancer] 2025 Apr; Vol. 23 (2), pp. 102302. Date of Electronic Publication: 2025 Jan 08.

Publikationsart: Journal Article; Clinical Trial, Phase II

Info zur Zeitschrift: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

MeSH-Schlagworte: Docetaxel*/administration & dosage , Docetaxel*/therapeutic use , Phenylthiohydantoin*/analogs & derivatives , Phenylthiohydantoin*/administration & dosage , Phenylthiohydantoin*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Benzamides*/administration & dosage , Androgen Antagonists*/administration & dosage , Androgen Antagonists*/therapeutic use , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/mortality, Humans ; Male ; Aged ; Middle Aged ; Nitriles/administration & dosage ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Aged, 80 and over ; Treatment Outcome

Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis.

Autoren: Wenzel M Cano Garcia C Humke C et al.

Quelle: European urology oncology [Eur Urol Oncol] 2025 Apr; Vol. 8 (2), pp. 364-371. Date of Electronic Publication: 2024 Aug 31.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

MeSH-Schlagworte: Thiohydantoins*/therapeutic use , Prostate-Specific Antigen*/blood , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/blood , Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/mortality, Humans ; Male ; Aged ; Middle Aged ; Neoplasm Metastasis ; Treatment Outcome ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/blood ; Aged, 80 and over ; Retrospective Studies ; Androstenes

Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study.

Autoren: Santoni M Büttner T Rescigno P et al.

Quelle: European urology oncology [Eur Urol Oncol] 2025 Apr; Vol. 8 (2), pp. 444-451. Date of Electronic Publication: 2024 Nov 29.

Publikationsart: Journal Article; Multicenter Study

Info zur Zeitschrift: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE

MeSH-Schlagworte: Thiohydantoins*/therapeutic use , Thiohydantoins*/adverse effects , Prostatic Neoplasms, Castration-Resistant*/drug therapy , Prostatic Neoplasms, Castration-Resistant*/pathology, Humans ; Male ; Aged ; Retrospective Studies ; Middle Aged ; Neoplasm Metastasis ; Aged, 80 and over ; Prostatic Neoplasms/drug therapy

Exploring the Therapeutic Potential of ¹⁷⁷ Lu-PSMA-617 in a Mouse Model of Prostate Cancer Bone Metastases.

Autoren: Peng CL Chen CT Tang IC

Quelle: International journal of molecular sciences [Int J Mol Sci] 2025 Jun 21; Vol. 26 (13). Date of Electronic Publication: 2025 Jun 21.

Publikationsart: Journal Article

Info zur Zeitschrift: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

MeSH-Schlagworte: Bone Neoplasms*/secondary , Bone Neoplasms*/radiotherapy , Bone Neoplasms*/drug therapy , Bone Neoplasms*/diagnostic imaging , Heterocyclic Compounds, 1-Ring*/therapeutic use , Heterocyclic Compounds, 1-Ring*/pharmacokinetics , Heterocyclic Compounds, 1-Ring*/pharmacology , Heterocyclic Compounds, 1-Ring*/chemistry , Dipeptides*/pharmacokinetics , Dipeptides*/therapeutic use , Dipeptides*/pharmacology , Dipeptides*/chemistry , Lutetium*/chemistry , Radioisotopes*/therapeutic use , Prostatic Neoplasms*/pathology , Radiopharmaceuticals*/pharmacokinetics , Radiopharmaceuticals*/therapeutic use , Radiopharmaceuticals*/pharmacology, Animals ; Male ; Mice ; Humans ; Cell Line, Tumor ; Disease Models, Animal ; Tissue Distribution ; Xenograft Model Antitumor Assays ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostate-Specific Antigen

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.

Autoren: Roubaud G Kostine M McDermott RS et al.

Quelle: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Mar 11; Vol. 218, pp. 115293. Date of Electronic Publication: 2025 Feb 06.

Publikationsart: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Info zur Zeitschrift: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

MeSH-Schlagworte: Abiraterone Acetate*/administration & dosage , Abiraterone Acetate*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Bone Density*/drug effects , Prednisone*/administration & dosage , Prednisone*/adverse effects , Prostatic Neoplasms*/drug therapy , Prostatic Neoplasms*/pathology, Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Absorptiometry, Photon ; Androgen Antagonists/adverse effects ; Androgen Antagonists/administration & dosage ; Docetaxel/administration & dosage ; Osteoporosis/chemically induced ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Treatment Outcome